Rodolfo Passalacqua - Concepedia

Author

Rodolfo Passalacqua

Also Known As

Alessio Cortellini, Antonella Pasqualini, Hector SotoParra, Melania Ranghitta, Michela Romanelli, Passalacqua, R., Passalacqua, Rodolfo, R PASSALACQUA, R Passalacqua, R. Lottici

275

Publications

11.5K

Citations

H-Index

Concepts

All Affiliations

Istituti Ospitalieri di Cremona University of Parma Fondazione IRCCS Istituto Nazionale dei Tumori Istituti di Ricovero e Cura a Carattere Scientifico Ospedale di Parma

About

Rodolfo Passalacqua is an author at Istituti Ospitalieri di Cremona specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	37	5K
2	Health Sciences	8	8	167
3	Nursing	1	1	16
4	Social Sciences	1	1	104
5	Cognitive Science	1	1	104

Rodolfo Passalacqua

Publications

9.4K

Citations

H-Index

Page 1

	Year	Citations
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Charles S. Fuchs, Jiří Tomášek, Filip Dumitru, The Lancet Surgical OncologyEsophageal CancerGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaMedicine	2013	2.2K
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts, New England Journal of Medicine	2016	2K
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, The Lancet Pembrolizumab Versus PaclitaxelGastrointestinal OncologyMedicineGastroenterologySurgery	2018	1.3K
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer Fausto Petrelli, Gianluca Tomasello, Karen Borgonovo, JAMA Oncology	2016	722
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Giancarlo Agnelli, Gualberto Gussoni, C. Bianchini, The Lancet Oncology ThrombosisMedicinePharmacologyDouble-blind StudyAmbulatory Patients	2009	591
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial Thomas Suter, Marion Procter, Dirk J. van Veldhuisen, Journal of Clinical Oncology	2007	563
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Nature Medicine	2022	268
Combination Therapy with Platinum and Etoposide of Brain Metastases from Breast Carcinoma Giorgio Cocconi, Renata Lottici, Giancarlo Bisagni, Cancer Investigation	1990	129
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Marco Colleoni, Weixiu Luo, Per Karlsson, The Lancet Oncology Breast OncologyMedicineCancer ManagementGynecologyBreast Cancer	2017	120
Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Fausto Roila, Maurizio Tonato, C. Basurto, Journal of Clinical Oncology Drug SafetyAntiemetic ActivityMedicinePharmacologyClinical Trials	1987	115

Page 1